Zahra Ramji, Co-Founder at MedInsights Unleashed, shared on LinkedIn:
“New Episode Alert with MedInsights Unleashed: Melanoma Breakthroughs: Science, Hope and Collaboration
At American Society of Clinical Oncology (ASCO) 2025, Dr. Elinor Barsh (DO) and Dr. Jacob Keeling (MD) with Sarah Cannon Research Institute unveiled findings that could reshape the future of melanoma treatment.
Why it matters for leaders and patients alike:
- Innovation with impact – ROR2-directed ADCs like Ozuriftamab Vedotin are redefining ‘guided chemotherapy,’ delivering precision with manageable side effects.
- Hope for the hardest cases – Durable responses in patients who had exhausted immune checkpoint inhibitors, including CTLA-4.
- Collaboration drives change – From mentorship to multi-center networks, breakthroughs come when science and people connect.
For patients and caregivers: Even rare subtypes like uveal melanoma are showing promise, with one patient remaining in complete response nearly 5 years after standard therapies had run out.
Listen to the full conversation here.
This is where cutting-edge science meets human resilience – transforming oncology from the lab bench to real lives.”
More posts featuring Zahra Ramji.